Endogenous neuroprotection in chronic neurodegenerative disorders: with particular regard to the kynurenines
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
• Introduction • The role of mitochondrial impairment and oxidative stress in neurodegeneration - Background - Parkinson’s disease - Huntington’s disease • Glutamate excitotoxicity in neurodegeneration - Background - Parkinson’s disease - Huntington’s disease • The kynurenine pathway - Historical overview - The biosynthesis of neuroactive kynurenines - Neuroactive kynurenines: sites of action • Neuroactive kynurenines in neurodegenerative disorders - Parkinson’s disease - Huntington’s disease • Endogenous neuroprotection in Parkinson’s and Huntington’s diseases - Background - L-carnitine - L-carnosine - Coenzyme Q10 - Creatine - Cysteamine/cystamine - Eicosapentaenoic acid - α-lipoic acid - Pyruvate - Taurine - Tocopherol - L-KYN/KYNA • Concluding remarks Parkinson’s disease (PD) and Huntington’s disease (HD) are progressive chronic neurodegenerative disorders that are accompanied by a considerable impairment of the motor functions. PD may develop for familial or sporadic reasons, whereas HD is based on a definite genetic mutation. Nevertheless, the pathological processes involve oxidative stress and glutamate excitotoxicity in both cases. A number of metabolic routes are affected in these disorders. The decrease in antioxidant capacity and alterations in the kynurenine pathway, the main pathway of the tryptophan metabolism, are features that deserve particular interest, because the changes in levels of neuroactive kynurenine pathway compounds appear to be strongly related to the oxidative stress and glutamate excitotoxicity involved in the disease pathogenesis. Increase of the antioxidant capacity and pharmacological manipulation of the kynurenine pathway are therefore promising therapeutic targets in these devastating disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiology of Parkinson's disease
de Lau, L. M., & Breteler, M. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70471-9 · Cited by 4,110
Ankarcrona, M., Dypbukt, J. M., Bonfoco, E., Zhivotovsky, B., Orrenius, S., Lipton, S. A., & Nicotera, P. (1995) · Neuron · doi:10.1016/0896-6273(95)90186-8 · Cited by 1,884 · cited 1×
“It is important that the occurrence of necrosis or apoptosis depends on the severity of the pathological stimuli [29, 30].”
BackgroundLeist, M., Single, B., Castoldi, A. F., Kühnle, S., & Nicotera, P. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.8.1481 · Cited by 1,871
Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways
Hardingham, G. E., Fukunaga, Y., & Bading, H. (2002) · Nature Neuroscience · doi:10.1038/nn835 · Cited by 1,686 · cited 1×
“The available data suggest that the activation of NMDARs (which facilitates the entry of cations, and in particular Ca(2) , into the neurons) at the extrasynaptic site is neurotoxic, whereas synaptic NMDAR activation promotes neuronal survival [69].”
BackgroundEarly mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines
Panov, A. V., Gutekunst, C.-A., Leavitt, B. R., Hayden, M. R., Burke, J. R., Strittmatter, W. J., & Greenamyre, J. T. (2002) · Nature Neuroscience · doi:10.1038/nn884 · Cited by 1,030
Cui, L., Jeong, H., Borovecki, F., Parkhurst, C. N., Tanese, N., & Krainc, D. (2006) · Cell · doi:10.1016/j.cell.2006.09.015 · Cited by 1,012
Effects of Coenzyme Q10 in Early Parkinson Disease: Evidence of Slowing of the Functional Decline
Shults, C. W. (2002) · Archives of Neurology · doi:10.1001/archneur.59.10.1541 · Cited by 984 · cited 1×
“Whereas low-dose administration was ineffective [186], higher doses of coenzyme Q10 exerted beneficial effects in early PD patients in a phase II, multicentre, randomized, parallel-group, placebo-controlled, double-blind, dosage-ranging clinical trial [187] and in a monocentre, parallel-group, placebo-controlled, doub…”
BackgroundMitochondria in the aetiology and pathogenesis of Parkinson's disease
Schapira, A. H. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70327-7 · Cited by 883
Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease
Zuccato, C., Valenza, M., & Cattaneo, E. (2010) · Physiological Reviews · doi:10.1152/physrev.00041.2009 · Cited by 848
Liu, Y., Wong, T. P., Aarts, M., Rooyakkers, A., Liu, L., Lai, T. W., Wu, D. C., Lu, J., Tymianski, M., Craig, A. M., et al. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.0116-07.2007 · Cited by 773 · cited 1×
“It has been shown that the NR2B-containing NMDARs predominate at the extrasynaptic site [70], and there is accumulating evidence that glutamate-induced excitotoxicity is mainly mediated by these NR2B-containing NMDAR channels [71].”
Background
Cited by
Lovelace, M. D., Varney, B., Sundaram, G., Lennon, M. J., Lim, C. K., Jacobs, K., Guillemin, G. J., & Brew, B. J. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.03.024 · Cited by 393
Tryptophan-kynurenine pathway is dysregulated in inflammation and immune activation
Zou, M.-H. (2015) · Frontiers in Bioscience · doi:10.2741/4363 · Cited by 361
A further update on the role of excitotoxicity in the pathogenesis of Parkinson’s disease
Ambrosi, G., Cerri, S., & Blandini, F. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-013-1149-z · Cited by 195
“Furthermore, KYNA was shown to reduce glutamate release at synapses by inhibiting a7nicotinic cholinergic receptors, whose activation promotes glutamate release at glutamatergic pre-synaptic terminals (Zádori et al. 2011).”
BackgroundThome, J., Ehlis, A.-C., Fallgatter, A. J., Krauel, K., Lange, K. W., Riederer, P., Romanos, M., Taurines, R., Tucha, O., Uzbekov, M., et al. (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.690535 · Cited by 130
“It has been shown (Lapin 2004; Vamos et al. 2009; Zadori et al. 2011; Mandi and Vecsei 2012) that the kynurenine pathway of the metabolism of tryptophan, the precursor molecule for both the serotonin and the kynurenine metabolic pathways, is the main one found in humans and in other mammals: about…”
Method
Metadata
- Authors
- Zádori, D., Klivényi, P., Plangár, I., Toldi, J., & Vécsei, L.
- Venue
- Journal of Cellular and Molecular Medicine
- Publisher
- Wiley
- Published
- 2011-04
- Volume
- 15
- Issue
- 4
- Pages
- 701-717
- ISSN
- 1582-1838 (ISSN-L)
- OpenAlex
- W2069370488
- Cited by
- 66
- References
- 30
- FWCI
- 1.06
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Endogenous neuroprotection in chronic neurodegenerative disorders: with particular regard to the kynurenines. https://app.cochat.ai/papers/10.1111/j.1582-4934.2010.01237.x
- The paper
- Zádori, D., Klivényi, P., Plangár, I., Toldi, J., & Vécsei, L. (2011). Endogenous neuroprotection in chronic neurodegenerative disorders: with particular regard to the kynurenines. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/j.1582-4934.2010.01237.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.